Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR446523 in Relapsed/Refractory Multiple Myeloma
NCT06630806Phase 1Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2024
- Primary completion
- May 2031
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, randomised, open-label trial of SAR446523 in multiple myeloma (MM) (3 arms), sponsored by Sanofi. Primary endpoints: Dose Limiting Toxicities at 28 days and Overall Response Rate at 24 months. Started Oct 2024; status: recruiting.
02
Drugs
SAR446523
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06630806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630806.